Alpha 2-adrenergic receptor subtype C (ALPHA-2C) antagonists for the treatment of sleep apnea
Arylpiperazines targeting α2C adrenergic receptors address the intolerance issue with CPAP by stabilizing airways, offering an effective treatment for obstructive and central sleep apnea and snoring.
Patent Information
- Application Number
- JP2021516568
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-09-25
- Filing Date
- 2019-09-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-09-19
AI Technical Summary
Current treatments for sleep-related breathing disorders such as obstructive sleep apnea and snoring, like continuous positive airway pressure (CPAP), are not tolerated by up to 50% of patients, necessitating the development of effective therapeutic agents.
Arylpiperazines of formula (I) act as α2C adrenergic receptor antagonists, inhibiting upper airway collapse and stabilizing the airway to prevent disorders like obstructive and central sleep apnea and snoring.
The arylpiperazines effectively prevent upper airway collapse and reduce symptoms of sleep-related breathing disorders, providing an alternative to CPAP for patients.
Smart Images

Figure 0007592007000003 
Figure 0007592007000001 
Figure 0007592007000002
Abstract
Description
[Technical field]
[0001] The present invention relates to alpha2-adrenergic receptor subtype C (alpha-2C) antagonists, in particular arylpiperazines of formula (I) for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring. [Background technology]
[0002] 2. Background of the Invention Obstructive sleep apnea (OSA) is a sleep-related breathing disorder characterized by repeated episodes of upper airway obstruction. During inspiration, upper airway patency is ensured by the interplay of two opposing forces. The dilator action of the upper airway musculature counteracts the negative intraluminal pressure that constricts the lumen. Active contraction of the diaphragm and other accessory respiratory muscles generates negative pressure in the airway and constitutes the drive for breathing. Upper airway stability is substantially determined by the coordination and contractile properties of the upper airway dilator muscles.
[0003] It is believed that upper airway collapse in OSA occurs at sleep onset because of reduced activity of some upper airway dilator muscles, resulting in an inability to maintain the anatomically vulnerable airway open. However, some upper airway dilator muscles, including the most important of the upper airway dilator muscles, the genioglossus, innervated by the hypoglossal nerve, can increase their activity during sleep in response to respiratory stimuli, potentially countering some of these changes at sleep onset. It has been observed that OSA patients have apnea-free intervals in which genioglossus activity is only 25-40% higher compared to sleep phases with a higher frequency of obstructive apnea (Jordan AS, White DP, Lo YL et al., "Airway dilator activity and lung volumes during stable breathing in obstructive sleep apnea." Sleep 2009, 32(3): 361-8). Noradrenaline is one of the most potent neuromodulators of hypoglossal motoneuron activity (Horner RL, Neuromodulation of hypoglossal motoneurons during sleep. Respir Physiol Neurobiol 2008, 164 (1-2): 179-196). A reduction in noradrenergic drive is thought to lead to a sleep-dependent decrease in hypoglossal motoneuron excitability that results in reduced upper airway dilator muscle activity, especially in the genioglossus muscle activity.
[0004] α2C adrenoceptors regulate the release of noradrenaline from central noradrenergic neurons. They are autoreceptors involved in presynaptic feedback inhibition of noradrenaline (Hein L. et al., "Two functionally distinct α2 adrenoceptors regulate sympathetic neurotransmission" Nature 1999, 402(6758): 181-184). Increasing the activity of motor neurons of the hypoglossal nerve via α2c adrenoceptor antagonism stabilizes the upper airway and protects it from collapse and obstruction. Furthermore, snoring can be inhibited via mechanisms of stabilization of the upper airway.
[0005] In simple snoring, there is no obstruction of the upper airway. The narrowing of the upper airway increases the inspiratory and expiratory flow rates. This, along with the relaxed muscles, causes fluttering of the soft tissues of the mouth and throat in the airstream. This slight vibration produces the typical snoring sound.
[0006] Obstructive snoring (upper airway resistance syndrome, heavy snoring, hypopnea syndrome) is caused by recurrent partial obstruction of the upper airway during sleep. This results in increased airway resistance and increased work of breathing with significant intrathoracic pressure fluctuations. Negative intrathoracic pressure development during inspiration can reach values that result from complete airway obstruction in OSA. The pathophysiological effects on the heart, circulation and sleep quality are the same as in obstructive sleep apnea. The etiology is likely to be the same as in OSA. Obstructive snoring is often a precursor to OSA. (Hollandt JH et al., Upper airway resistance syndrome (UARS)-obstructive snoring) HNO 2000, 48(8): 628-634).
[0007] Central sleep apnea (CSA) occurs as a result of impaired brain function or respiratory control. CSA is characterized by recurrent periods during sleep in which respiratory drive is insufficient, ventilation is insufficient or absent, and gas exchange is impaired. CSA has several manifestations. These include high altitude-induced periodic breathing, idiopathic CSA (ICSA), opiate-induced central apnea, obesity hypoventilation syndrome (OHS), and Cheyne-Stokes respiration (CSB). Although the exact triggering mechanisms involved in the various types of CSA may differ considerably, unstable ventilatory drive during sleep is the main underlying feature (Eckert DJ et al., "Central sleep apnea: pathophysiology and treatment." Chest 2007, 131(2): 595-607).
[0008] US 2018 / 0235934 A1 describes a method for treating disorders such as obstructive sleep apnea using an agent for promoting excitability of hypoglossal motoneurons. As an agent for promoting excitability of hypoglossal motoneurons, a disinhibitor and / or stimulator of central noradrenergic neurons is described. In some embodiments, the disinhibitor of central noradrenergic neurons is an alpha2-adrenergic receptor antagonist, such as yohimbine or an alpha2-adrenergic receptor subtype A (alpha-2A) antagonist or an alpha2-adrenergic receptor subtype C (alpha-2C) antagonist. The alpha2-adrenergic receptor antagonist is selected from the group consisting of atipamezole, MK-912, RS-79948, RX821002, [3H]2-methoxy-idazoxan, and JP-1302.
[0009] The α2C-adrenergic receptor belongs to the G protein-coupled receptor family. Besides the different α1-adrenergic receptors, there are three different α2-adrenergic receptor subtypes (α2A, α2B, α2C). These are involved in mediating several diverse physiological actions in different tissues upon stimulation by endogenous catecholamines (epinephrine, norepinephrine) induced via synapses or blood. The α2-adrenergic receptors play an important physiological role mainly in the cardiovascular and central nervous systems. The α2A- and α2C-adrenergic receptors are the main autoreceptors involved in the presynaptic feedback inhibition of noradrenaline in the central nervous system. The potency and affinity of noradrenaline at the α2C-adrenergic receptors is higher than at the α2A-adrenergic receptors. α2C-adrenergic receptors inhibit noradrenaline release at low concentrations of endogenous noradrenaline, whereas α2A-adrenergic receptors inhibit noradrenaline release at high concentrations of endogenous noradrenaline (Uys MM et al. "Selective targeting of α2C-adrenergic receptors in cognition, depression, and schizophrenia - new developments and future perspectives." Frontiers in Psychiatry2017 Aug 14:8:144 doi: 10.3389 / fpsyt.2017.00144. eCollection 2017).
[0010] Arylpiperazines as α2-adrenergic receptor subtype C (α-2C) antagonists and their preparations and their use are known from WO 2010 / 058060 A1, which discloses that the compounds are useful for treating disorders such as stress, Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive-compulsive disorder, Tourette's syndrome, blepharospasm or other focal dystonia, temporal lobe epilepsy with psychosis, drug-induced psychosis, Huntington's disease, disorders caused by fluctuations in the level of sex hormones, panic disorder, Alzheimer's disease or mild cognitive impairment.No use of these compounds is disclosed for treating sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] US 2018 / 0235934 A1 [Patent Document 2] WO 2010 / 058060 A1
[0012] [Non-Patent Document 1] Jordan AS, White DP, Lo YL et al. Sleep 2009, 32(3): 361-8 [Non-Patent Document 2] Horner RL Respir Physiol Neurobiol 2008, 164 (1-2): 179-196 [Non-Patent Document 3] Hein L. et al., Nature 1999, 402(6758): 181-184 [Non-Patent Document 4] Hollandt JH et al., HNO 2000, 48(8): 628-634 [Non-Patent Document 5] Eckert DJ et al., Chest 2007, 131(2): 595-607 [Non-Patent Document 6] Uys MM et al., Frontiers in Psychiatry2017-08-14:8:144 doi: 10.3389 / fpsyt.2017.00144. eCollection 2017 Summary of the Invention [Problem to be solved by the invention]
[0013] The current gold standard treatment for OSA patients is Continuous Positive Airway Pressure (CPAP). The positive airflow pressure generated by the airflow turbine splint opens the upper airway and reverses all potential causes of pharyngeal collapse, thereby preventing hypopnea, apnea and sleep fragmentation. Unfortunately, up to 50% of all OSA patients cannot tolerate CPAP for long periods of time (M. Kohler, D. Smith, V. Tippett et al., Thorax 2010 65(9):829-32: "Predictors of Long-Term Compliance with Continuous Positive Airway Pressure"). Thus, there remains a need to find an effective therapeutic agent for the treatment and / or prevention of sleep-related breathing disorders, such as obstructive sleep apnea. Thus, the object of the present invention is to provide an effective therapeutic agent for the treatment and / or prevention of sleep-related breathing disorders, such as obstructive sleep apnea, central sleep apnea and snoring. [Means for solving the problem]
[0014] Surprisingly, it has now been found that the arylpiperazines of formula (I) of the present invention inhibit upper airway collapsibility and are therefore suitable for the manufacture of medicaments for use in the treatment and / or prevention of sleep related breathing disorders, preferably obstructive and central sleep apnea and snoring. [Brief description of the drawings]
[0015] [Figure 1] FIG. 1: Effect of the α2-adrenergic receptor subtype C (α-2C) antagonist of formula (I) (((S)-1-(((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine) on upper airway collapsibility at different levels of negative pressure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The present invention relates to a compound of formula (I) for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring. TIFF0007592007000001.tif39170 [In the ceremony X is O, S or CH2; Z is -[CH2] n - and; A, B, D and E are independently C or N, with the proviso that at least three of A, B, D and E are C; R1 is H, halogen, hydroxy, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, hydroxy(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN , (R5)2N-, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)-, SH-(C1-C6)alkyl, hydroxy(C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl-S-(C1-C6)alkyl, hydroxy(C1-C6)alkyl-S(Op)-(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl-S(Op)-(C1-C6)alkyl or furyl; R2 is H, halogen, (C1-C6)alkyl, (C1-C6)alkoxy or hydroxy(C1-C6)alkyl; R3 is H, halogen, (C1-C6)alkyl or phenyl; R4 is halogen, hydroxy, (C1-C6)alkyl, (C1-C6)alkoxy, CN or (R5)2N-; Each R5 is independently H, (C1-C6)alkyl, or (C1-C6)alkoxy(C1-C6)alkyl; m is 0, 1 or 2; n is 1 or 2; p is 1 or 2. and salts, solvates, and solvates of the salts thereof. In a possible subgroup of compounds of formula I, X is O. In a further possible subgroup of compounds of formula I, A, B, D and E are C. In another possible subgroup of compounds of formula I, A is N and B, D and E are C. In a further possible subgroup of compounds of formula I, n is 1. In a further possible subgroup of compounds of formula I, n is 2. In another possible subgroup of compounds of formula I, X is O, S, or CH2; Z is -[CH2] n - and; A is C or N; B, D and E are C; R1 is H, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; R3 is H, (C1-C6)alkyl or phenyl; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 1 or 2.
[0017] In a further embodiment of the present invention X is O; Z is -[CH2] n - and; A is C or N; B, D and E are C; R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; R3 is H, (C1-C6)alkyl or phenyl; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 1 or 2.
[0018] In a further embodiment of the present invention X is O; Z is -[CH2] n - and; A, B, D and E are C; R1 is (C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H or halogen; R3 is H; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 1 or 2.
[0019] In a further embodiment of the present invention X is O; Z is -[CH2] n - and; A is N; B, D and E are C; R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H or halogen; R3 is H; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 1 or 2.
[0020] In a further embodiment of the present invention X is O; Z is i-[CH2] n - and; A is N; B, D and E are C; R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; R3 is H, (C1-C6)alkyl or phenyl; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 1.
[0021] In a further embodiment of the present invention X is O; Z is -[CH2] n - and; A is N; B, D and E are C; R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; R3 is H, (C1-C6)alkyl or phenyl; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 2.
[0022] In a further embodiment of the present invention X is O; Z is -[CH2] n - and; A, B, D and E are C; R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; R3 is H, (C1-C6)alkyl or phenyl; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 1.
[0023] In a further embodiment of the present invention X is O; Z is -[CH2] n - and; A, B, D and E are C; R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, halo(C1-C6)alkoxy, halo(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy-(C=O)-, CN, (R5)2N-(C1-C6)alkyl, (R5)2N-(C=O)- or furyl; R2 is H, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; R3 is H, (C1-C6)alkyl or phenyl; Each R5 is independently H or (C1-C6)alkyl; m is 0; n is 2.
[0024] In a preferred embodiment, the present invention relates to compounds of formula (I) and their salts, solvates and solvates of salts, selected from the following group for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring: 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)benzoate methyl, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)phenyl)methanol, 1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)benzonitrile , (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)phenyl)methanamine, 1-(2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)phenyl)-N-methylmethanamine, 1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(ethoxymethyl)phenyl)piperazine, 2-(2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin 1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine, (S)-(2-(4-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-piperazin-1-yl)pyridin-3-yl)methanol, (S)-(2-(4-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-piperazin-1-yl)pyridin-3 -yl)methanol hydrochloride, (S)-1-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine hydrochloride, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-((2-fluoroethoxy)methyl)pyridin-2-yl)piperazine, 1-(2,3-dichlorophenyl)-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazine, (2-(4-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)pyridin-3-yl)methanol, (S)-(2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)pyridin-3-yl)methanol, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, (R)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl) methyl)-4-(2-(methoxymethyl)phenyl)piperazine, (S)-(2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)phenyl)methanol, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine, (1-((2,3-dihydrobenzo[b][1,4]oxathiin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, 1 -(chroman-2-ylmethyl)-4-(2-(methoxymethyl)phenyl)piperazine, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)-6-fluorophenyl)methanol, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)-3-fluorophenyl)methanol, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)-5 -fluorophenyl)methanol, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-propylphenyl)piperazine, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(trifluoromethoxy)phenyl)piperazine, (S)-1-(biphenyl-3-yl)-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazine, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(furan-2-yl)phenyl)piperazine, (S)-ethyl-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)benzoate, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-o-tolylpiperazine, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-m -tolylpiperazine, (S)-(3-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)-4-methylphenyl)methanol, (S)-(3-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)phenyl)methanol, (S)-2-(2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)phenyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)ethanol, 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)methyl benzoate, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)phenyl)methanol, 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)nicotinonitrile, 2-(4- ((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)nicotinamide, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)pyridin-3-yl)methanol and (S)-(2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)pyridin-3-yl)methanol.
[0025] In a more preferred embodiment, the present invention relates to compounds of formula (I) and their salts, solvates and solvates of salts selected from the following group: (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, (R)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, (2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(methoxymethyl)phenyl)piperazine, (R ... (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(2-(furan-2-yl)phenyl)piperazine, (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-o-tolylpiperazine, 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-1,4-diazepam-1-yl)benzoate and (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine.
[0026] In the most preferred embodiment, the compound of the invention is (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine or (S)-1-(((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-([ 11 C]-Methoxymethyl)pyridin-2-yl)piperazine.
[0027] As used herein, terms have the meanings given below: As used below, the term "at least one" refers to one or more, e.g., one.
[0028] The term "hydroxy" as used herein, by itself or as part of another group, refers to an --OH group.
[0029] As used herein, "(C1-C6)alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms. Representative examples of (C1-C6)alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, and n-hexyl.
[0030] The term "(C1-C6)alkoxy" as used herein, alone or as part of another group, refers to a (C1-C6)alkyl group (as defined herein) that is attached to the parent molecular moiety through an oxygen atom. Representative examples of (C1-C6)alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, 2,2-dimethylpropoxy, 3-methylbutoxy, and n-hexoxy.
[0031] The terms "halo" or "halogen" as used herein, by themselves or as part of another group, mean fluorine, chlorine, bromine, or iodine.
[0032] The term "hydroxy(C1-C6)alkyl" as used herein refers to at least one hydroxy group, as defined herein, appended to the parent molecular moiety via a (C1-C6)alkyl group, as defined herein, either alone or as part of another group. Representative examples of hydroxy(C1-C6)alkyl include, but are not limited to, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2-dihydroxyethyl, 1-hydroxypropyl, 3-hydroxypropyl, 1-hydroxy-1-methylethyl, and 1-hydroxy-1-methylpropyl.
[0033] The term "(C1-C6)alkoxy(C1-C6)alkyl" as used herein, either by itself or as part of another group, refers to at least one (C1-C6)alkoxy group appended to the parent molecular moiety through a (C1-C6)alkyl group, as defined herein. When there are multiple (C1-C6)alkoxy groups, the (C1-C6)alkoxy groups can be the same or different.
[0034] Representative examples of (C1-C6)alkoxy(C1-C6)alkyl include, but are not limited to, methoxymethyl, ethoxymethyl, propoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, 2,2-dimethoxyethyl, 1-methyl-2-propoxyethyl, 1-methoxy-1-methylethyl, and 4-methoxybutyl.
[0035] The term "hydroxy(C1-C6)alkoxy" as used herein refers to at least one hydroxy group, as defined herein, attached to the parent molecular moiety via a (C1-C6)alkoxy group, as defined herein, either alone or as part of another group. Representative examples of hydroxy(C1-C6)alkoxy include, but are not limited to, hydroxymethoxy, dihydroxymethoxy, 2-hydroxyethoxy, 2-hydroxypropoxy, 3-hydroxypropoxy, 2-hydroxybutoxy, and 2-hydroxy-1-methylethoxy.
[0036] The term "(C1-C6)alkoxy(C1-C6)alkoxy" as used herein refers to at least one (C1-C6)alkoxy group, as defined herein, attached to the parent molecular moiety through a (C1-C6)alkoxy group, as defined herein, either alone or as part of another group. The (C1-C6)alkoxy groups may be the same or different. Representative examples of (C1-C6)alkoxy(C1-C6)alkoxy include, but are not limited to, methoxymethoxy, propoxymethoxy, 2-methoxyethoxy, 2-ethoxyethoxy, 2-butoxyethoxy, 2,2-dimethoxyethoxy, 1-methoxy-2-protoxyethoxy, 2-methoxypropoxy, and 4-methoxybutoxy.
[0037] As used herein, "halo(C1-C6)alkoxy" refers to at least one halogen, as defined herein, attached to the parent molecular moiety via a (C1-C6)alkoxy group, as defined herein, either alone or as part of another group. When there are several halogens, the halogens may be the same or different. Representative examples of halo(C1-C6)alkoxy include, but are not limited to, fluoromethoxy, chloromethoxy, difluoromethoxy, trifluoromethoxy, 2-bromoethoxy, 2,2,2-trichloroethoxy, 3-bromopropoxy, 2-chloropropoxy, and 4-chlorobutoxy.
[0038] As used herein, the phrase "compounds of the invention" refers to compounds of Formula I.
[0039] In the pharmaceutical field, pharma- ceutically acceptable salts, such as acid addition salts, are known, both with organic and inorganic acids.Representative examples of pharma-ceutically acceptable acid addition salts include, but are not limited to, chloride, bromide, sulfate, nitrate, phosphate, sulfonate, methanesulfonate, formate, tartrate, maleate, citrate, benzoate, salicylate, ascorbate, acetate and oxalate.
[0040] Hydrates or solvates are according to the present invention as forms of the compounds of formula (I) that in the solid or liquid state form molecular compounds or form complexes by hydration with water or coordination with solvent molecules. Examples of hydrates are sesquihydrates, monohydrates, dihydrates or trihydrates. Hydrates or solvates of salts of the compounds according to the present invention are also suitable.
[0041] Pharmaceutically acceptable esters may be prepared by known methods, using pharmaceutical acceptable acids that are conventional in the pharmaceutical field and retain the pharmacological properties of the free form, if possible.Non-limiting examples of these esters include esters of aliphatic or aromatic alcohols.Representative examples of pharmaceutical acceptable esters include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and benzyl esters.
[0042] The present invention includes within its scope the possible geometric isomers of the compounds, such as Z and E isomers (cis and trans isomers), as well as all possible optical isomers, such as diastereomers and enantiomers of the compounds. Moreover, the present invention includes within its scope both the individual isomers and any mixtures thereof, such as racemic mixtures. The individual isomers may be obtained using the corresponding isomeric forms of the starting materials, or they may be separated after preparation of the terminal compounds according to conventional separation methods. To separate optical isomers, such as enantiomers, from their mixtures, conventional separation methods, such as fractional crystallization, may be used.
[0043] The preparation of compounds of formula (I) and their action as α2C antagonists for the treatment of diseases or conditions of the peripheral or central nervous system are generally disclosed in WO-A 2010 / 058060, in particular the compounds which are an explicit part of the description of the present invention and are incorporated herein by reference.
[0044] As used herein, the term "effective amount" means an amount of a compound of formula (I) effective in treating and / or preventing sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0045] The present invention relates to (α-2C) antagonists of formula (I), in particular aryl-piperazines of formula (I), for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0046] The present invention further relates to the use of compounds of formula (I) for the preparation of a medicament for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0047] A further subject of the present invention is the use of a combination of one or more compounds of formula (I) with one or more other active compounds in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0048] A further subject of the present invention is a pharmaceutical composition comprising at least one compound of formula (I) in combination with one or more inert, non-toxic, pharma- ceutical suitable excipients for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0049] The present invention further relates to pharmaceutical compositions comprising a combination with one or more other active compounds in combination with one or more inert, non-toxic, pharmacologic suitable excipients for use in methods for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0050] The present invention is also directed to a method for the treatment and / or prevention of sleep-related breathing disorders by systemically and / or locally administering a therapeutically effective amount of at least one compound of formula (I) or at least one compound of formula (I) in combination with inert, non-toxic pharmaceutically acceptable excipients.
[0051] A further subject of the present invention is a combination of one or more compounds of formula (I) with one or more other active compounds for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0052] The arylpiperazines of formula (I) according to the invention can be used alone or, if necessary, in combination with one or more other pharmacologically active substances, as long as this combination does not result in undesirable and unacceptable side effects. Preferred examples of combinations suitable for the purpose of treating sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring, include: Respiratory stimulants, by way of example and preferably theophylline, doxapram, nikethamide, caffeine; Psychostimulants, for example and preferably modafinil or armodafinil; Amphetamines and amphetamine derivatives, such as, by way of example and preferably, amphetamine, methamphetamine or methylphenidate; Serotonin reuptake inhibitors, by way of example and preferably fluoxetine, paroxetine, citalopram, escitalopram, sertraline, fluvoxamine or trazodone; Serotonin precursors, for example and preferably L-tryptophan; selective serotonin-noradrenaline reuptake inhibitors, for example and preferably venlafaxine or duloxetine; noradrenergic and specific serotonergic antidepressants, for example and preferably mirtazapine; Selective noradrenaline reuptake inhibitors, such as, by way of example and preferably, reboxetine or atomoxetine; Tricyclic antidepressants, by way of example and preferably amitriptyline, protriptyline, doxepin, trimipramine, imipramine, clomipramine or desipramine; Muscarinic receptor antagonists, for example and preferably oxybutynin; GABA agonists, for example and preferably baclofen; Glucocorticoids, by way of example and preferably fluticasone, budesonide, beclomethasone, mometasone, tixocortol or triamcinolone; Cannabinoid receptor agonists; Carboanhydrase inhibitors, by way of example and preferably acetazolamide, methazolamide or diclophenamide; Opioid and benzodiazepine receptor antagonists, by way of example and preferably flumazenil, naloxone or naltrexone; Cholinesterase inhibitors, by way of example and preferably neostigmine, pyridostigmine, physostigmine, donepezil, galantamine or rivastigmine; Appetite suppressants, such as, by way of example and preferably, sibutramine, opiramate, phentermine, lipase inhibitors or cannabinoid receptor antagonists; Mineralocorticoid receptor antagonist.
[0053] A preferred subject of the present invention is a combination of one or more compounds of formula (I) with one or more other active compounds selected from the group consisting of muscarinic receptor antagonists, mineralocorticoid receptor antagonists, diuretics, corticosteroids, for use in a method for the treatment and / or prevention of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
[0054] In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a muscarinic receptor antagonist, by way of example and with preference oxybutynin.
[0055] In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a mineralocorticoid receptor antagonist, by way of example and with preference spironolactone, eplerenone or finerenone.
[0056] In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a diuretic, by way of example and with preference furosemide, bumetanide, torsemide, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichlormethiazide, chlorthalidone, indapamide, metolazone, quinethazone, acetazolamide, dichlorphenamide, methazolamide, glycerol, isosorbide, mannitol, amiloride or triamterene.
[0057] In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with, by way of example and preferably, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, beclomethasone, flunisolide, budesonide or fluticasone.
[0058] If necessary, the arylpiperazines of formula (I) according to the invention can also be used in conjunction with the use of one or more medical technical devices or auxiliaries, provided this does not lead to undesirable and unacceptable side effects. Medical devices and auxiliaries suitable for such combined applications are, by way of example and preferably, the following: Positive pressure ventilation devices such as CPAP (Continuous Positive Airway Pressure) machines, BiPAP (Bilevel Positive Airway Pressure) machines, and IPPV (Intermittent Positive Airway Pressure) machines; Hypoglossal nerve stimulator; Intra-oral appliances, for example and preferably prosthesis appliances; Disposable nasal valves; Nasal stent.
[0059] The arylpiperazines of formula (I) according to the invention can act systemically and / or locally and for this purpose can be administered in any suitable manner, for example by oral, parenteral, pulmonary, intrapulmonary (inhalation), nasal, intranasal, pharyngeal, lingual, sublingual, buccal, rectal, dermal, transdermal, conjunctival or auricular route or as an implant or stent.
[0060] A further subject of the present invention are pharmaceutical compositions comprising a compound of formula (I) for systemic and / or local administration by oral, parenteral, pulmonary, intrapulmonary (inhalation), nasal, intranasal, pharyngeal, lingual, sublingual, buccal, rectal, dermal, transdermal, conjunctival or auricular route or as an implant or stent. The preferred administration route is the oral route.
[0061] For these administration routes, the compounds according to the invention can be administered in suitable dosage forms.
[0062] For oral administration, dosage forms that function according to the invention release the compounds according to the invention rapidly and / or in an improved manner and contain the compounds in crystalline and / or amorphous and / or soluble form, such as tablets (e.g. uncoated or coated tablets having a gastro-resistant or slow-dissolving or insoluble coating that controls the release of the compounds according to the invention), buccal or film / wafer, film / lyophilisate, capsules (e.g. hard or soft gelatin capsules), drags, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
[0063] Parenteral administration can be performed by omitting the absorption step (e.g., intravenous, intraarterial, intracardiac, intraspinal or intralumbar administration) or by omitting administration that involves absorption (e.g., intramuscular, subcutaneous, intradermal, transdermal or intraperitoneal administration). Suitable dosage forms for parenteral administration include injections and infusions in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
[0064] Other suitable routes of administration are, for example, inhaled formulations (including powder inhalers and nebulizers), nasal drops, solutions or sprays, tablets for sublingual administration, tablets for sublingual or buccal administration, tablets, films / wafers or capsules, suppositories, oral or ophthalmic formulations, vaginal capsules, aqueous suspensions (lotions, shakeable mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. plasters), milk, pastes, foams, dusting powders, implants or stents.
[0065] Oral or parenteral administration, particularly oral and intravenous administration, is preferred.
[0066] The compound according to the present invention can be converted into the described dosage form.This can be carried out in a manner known per se by mixing with inert and non-toxic pharma- ceutically suitable additives.These additives include carriers (e.g., microcrystalline cellulose, lactose, mannitol), solvents (e.g., liquid polyethylene glycol), emulsifiers and dispersants or wetting agents (e.g., sodium dodecyl sulfate, polyoxysorbitan oleate), binders (e.g., polyvinylpyrrolidone), synthetic and natural polymers (e.g., albumin), stabilizers (e.g., antioxidants such as ascorbic acid), colorants (e.g., inorganic pigments such as iron oxides) and flavors or odor correctors.
[0067] In general, to achieve effective results in parenteral administration, it has been found to be advantageous to administer an amount of about 0.001 to 10 mg / kg, preferably about 0.01 to 1 mg / kg of body weight. In oral administration, the dosage is about 0.01 to 100 mg / kg, preferably about 0.01 to 20 mg / kg, and quite preferably 0.1 to 15 mg / kg of body weight.
[0068] However, it may be necessary to deviate from these amounts depending on the body weight, the route of administration, the individual response to the active substance, the nature of the formulation, the time and interval at which the administrations are carried out, etc. Thus, in some cases it may be sufficient to maintain below the minimum amounts given above, whereas in other cases it may be necessary to exceed the prescribed upper limits. In the case of large doses, it is advisable to administer these in several divided doses over the course of the day.
[0069] The following examples illustrate the invention, but the invention is not limited to them.
[0070] Working Example A. Experimental Method The advantageous pharmacological properties of the compounds of this invention can be determined by the following methods. The therapeutic potential of the compounds of formula (I) of the present invention in sleep apnea has been evaluated preclinically in a porcine model of obstructive sleep apnea (OSA). Using negative pressure, it is possible to induce collapse and thus upper airway obstruction in anesthetized, spontaneously breathing pigs (Wirth KJ et al., Sleep 36(5),(2013) pp.699-708). The model uses German Landrace pigs. The pigs are anesthetized and the tracheotomy is performed. Two tracheal tubes are inserted into the trachea, one in the rostral part and the other in the caudal part of the trachea. Using a connecting piece, the rostral cannula is connected to a tube to the negative pressure device and to the distal tracheal cannula. The distal tracheal cannula is further connected to a tube with an open end to the atmosphere via a connecting piece that served for free tracheal breathing, circumvoluting the upper airway. By appropriate opening and clamping of the breathing of these tubes, it is possible to switch from nasal breathing to breathing through the caudal tracheal cannula, circumvoluting the upper airway, connecting the (separated) upper airway to the negative pressure device, and inducing an airflow in the inspiratory direction.
[0071] At certain points, the collapsibility of the upper airway is tested by breathing through a caudal cannula and applying negative pressures of -50, -100 and -150 cm of water (cm H2O) to the upper airway. This causes the upper airway to collapse, which is manifested by an interruption of airflow and a drop in ductal pressure. This test is performed before and at regular intervals after administration of the test substance. An appropriately effective test substance is able to prevent this airway collapse during the inspiratory phase.
[0072] In this porcine model of OSA, an alpha-2-adrenergic receptor subtype C (alpha-2C) antagonist of formula (I) (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine administered as an intravenous bolus of 1.5 mg / kg, followed by an intravenous infusion of 0.475 mg / kg / h for 4 hours, prevented upper airway collapse at all negative pressures of -50, -100, and -150 cm for up to 5 hours.
[0073] [Table 1]
[0074] Figure 1: Effect of an alpha2-adrenergic receptor subtype C (alpha-2C) antagonist of formula (I) (((S)-1-(((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine) administered as an intravenous bolus injection of 1.5 mg / kg followed by an intravenous dose of 0.475 mg / kg / hour for 4 hours on upper airway collapsibility at different levels of negative pressure. Percentage of pigs not collapsing is shown. Mean values.
[0075] From the above data it can be deduced that α2-adrenergic receptor subtype C (α-2C) antagonists of formula (I) are suitable for the treatment of sleep-related breathing disorders, preferably obstructive and central sleep apnea and snoring.
Claims
1. 1. A pharmaceutical composition for use in a method for the treatment and / or prevention of sleep-related breathing disorders, comprising a compound or a salt, solvate, or solvate of said salt, wherein the compound is (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine, and the sleep-related breathing disorder is obstructive and central sleep apnea and snoring.
2. A combination of a first compound and one or more other active compounds for the treatment and / or prevention of sleep-related breathing disorders, wherein said first compound is (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine or a salt, solvate, or solvate of said salt, and the sleep-related breathing disorders are obstructive and central sleep apnea and snoring.
3. 1. A pharmaceutical composition for use in a method for the treatment and / or prevention of sleep-related breathing disorders comprising a first compound in combination with one or more inert, non-toxic, pharma- ceutical suitable excipients, wherein said first compound is (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine or a salt, solvate, or solvate of said salt, and wherein the sleep-related breathing disorders are obstructive and central sleep apnea and snoring.
4. A pharmaceutical composition for the use according to claim 1 comprising the combination according to claim 2 in combination with one or more inert, non-toxic pharma- ceutically suitable excipients.
5. 1. A pharmaceutical composition for the treatment and / or prevention of sleep-related breathing disorders, said treatment and / or prevention being by systemic and / or local administration of a therapeutically effective amount of a compound or a medicament comprising a compound in combination with an inert, non-toxic, pharma- ceutical suitable excipient, wherein said compound is (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine or a salt, solvate, or solvate of said salt, and wherein the sleep-related breathing disorders are obstructive and central sleep apnea and snoring.
6. 6. The pharmaceutical composition of claim 5, wherein the medicament further comprises at least one additional active compound selected from the group consisting of muscarinic receptor antagonists, mineralocorticoid receptor antagonists, diuretics and corticosteroids.
7. 1. A pharmaceutical composition comprising a compound in combination with one or more additional active ingredients selected from the group consisting of muscarinic receptor antagonists, mineralocorticoid receptor antagonists, diuretics and corticosteroids, wherein said compound is (S)-1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine or a salt, solvate, or solvate of said salt.
Citation Information
Patent Citations
Keiryoseikeitai
JP1976023513A
2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivative as an alpha-2C antagonist for use in the treatment of peripheral and central nervous system diseases
JP2010534197A
Use of arylpiperazines and alpha-2C antagonists
JP2012509302A
NOHNO2000,48
Noradrenergic drug treatment of obstructive sleep apnea
US20180235934A1
